Superworth

Veru revenue VERU

Sales by quarter and over the last twelve months, from 2010.

Last 12 months, to Sep 30, 2024
$16.9M
Latest quarter, Q4 FY24
$6.7M
+72% on a year earlier
Fiscal year 2024
$16.9M
+4% on the year before

Veru's revenue was $16.9M over the twelve months to Sep 30, 2024, up 4% on a year earlier.

In its latest quarter, Q4 FY24, it was $6.7M, up 72% on the same quarter a year before.

Over the five fiscal years to FY2024 it shrank 12% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2024$16.9M+4%
FY2023$16.3M−59%
FY2022$39.4M−36%
FY2021$61.3M+44%
FY2020$42.6M+34%
FY2019$31.8M+100%
FY2018$15.9M+16%
FY2017$13.7M−38%
FY2016$22.1M−32%
FY2015$32.6M+33%
FY2014$24.5M−22%
FY2013$31.5M−10%
FY2012$35M+89%
FY2011$18.6Mn/a
FY2010n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q4 FY24$6.7M+72%$16.9M
Q3 FY24$4M+18%$14.1M
Q2 FY24$4.1M−37%$13.5M
Q1 FY24$2.1M−15%$15.9M
Q4 FY23$3.9M+49%$16.3M
Q3 FY23$3.3M−65%$15M
Q2 FY23$6.6M−49%$21.3M
Q1 FY23$2.5M−82%$27.7M
Q4 FY22$2.6M−83%$39.4M
Q3 FY22$9.6M−46%$52.4M
Q2 FY22$13M−2%$60.5M
Q1 FY22$14.1M−3%$60.8M

Against its peers

Companies in Drug Manufacturers - General nearest Veru's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
VERUVerun/m
ATNMActinium Pharmaceuticalsn/m
SPROSpero Therapeutics$47M−3% a year
LFVNLifevantage$182.6M−20% a year
NATRNatures Sunshine Products$492M+7% a year
Peer median$182.6M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Veru

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.